Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 5/20 | 0.49 |
| ▸ | ARG1 | P05089 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 9/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.39 |
| ▸ | PLAU | P00749 | 1/20 | 0.37 |
| ▸ | PLAUR | Q03405 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30357425 | 0.91 | DPP4 (0.50) | DPP4ARG1DPP7DPP8 | |
| SCHEMBL3346333 | 0.90 | DPP4 (0.49) | DPP4ARG1DPP7DPP8 | |
| SCHEMBL16310466 | 0.90 | DPP4 (0.49) | DPP4ARG1DPP7DPP8 | |
| SCHEMBL4702393 | 0.86 | HSD17B10 (0.46) | DPP4 | |
| SCHEMBL24965932 | 0.85 | DPP4 (0.42) | DPP4ARG1DPP7DPP8PLAU | |
| SCHEMBL2906864 | 0.84 | TSHR (0.52) | — | |
| SCHEMBL24965915 | 0.83 | ALDH1A1 (0.51) | DPP4ARG1DPP7DPP8 | |
| Trifluoroacetic Acid SCHEMBL6824630 | 0.82 | DPP8 (0.43) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL24966088 | 0.79 | DPP4 (0.41) | DPP4ARG1DPP7DPP8 | |
| SCHEMBL24963362 | 0.79 | DPP4 (0.44) | DPP4ARG1DPP7DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346752-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2023-11-02 | — | — | US | disclosed |
| US-20230346752-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2023-11-02 | — | — | US | disclosed |
| US-20230293497-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230293497-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2023-09-21 | — | — | US | disclosed |
| US-11717514-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230000836-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2023-01-05 | — | — | US | disclosed |
| US-11369590-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2022-06-28 | — | — | US | disclosed |
| US-11344623-B2 | Cholecystokinin B receptor targeting for imaging and therapy | PURDUE RESEARCH FOUNDATION (US) | 2022-05-31 | — | — | US | disclosed |
| US-11318121-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210338641-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2021-11-04 | — | — | US | disclosed |
| WO-2010045598-A2 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2010-04-22 | — | — | WO | disclosed |
| US-20100048490-A1 | BINDING LIGAND LINKED DRUG DELIVERY CONJUGATES OF TUBULYSINS | ENDOCYTE, INC. | 2010-02-25 | — | — | US | disclosed |
| US-20100048490-A1 | BINDING LIGAND LINKED DRUG DELIVERY CONJUGATES OF TUBULYSINS | ENDOCYTE, INC. | 2010-02-25 | — | — | US | disclosed |
| US-20100004276-A1 | VITAMIN RECEPTOR BINDING DRUG DELIVERY CONJUGATES | VLAHOV IONTCHO R | 2010-01-07 | — | — | US | disclosed |
| WO-2009026177-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2009-02-26 | — | — | WO | disclosed |
| WO-2009002993-A1 | CONJUGATES CONTAINING HYDROPHILIC SPACER LINKERS | ENDOCYTE, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| US-20080280937-A1 | Ligand Conjugates of Vinca Alkaloids, Analogs, and Derivatives | ENDOCYTE, INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080248052-A1 | Vitamin receptor binding drug delivery conjugate | ENDOCYTE, INC. | 2008-10-09 | — | — | US | disclosed |
| WO-2008112873-A2 | BINDING LIGAND LINKED DRUG DELIVERY CONJUGATES OF TUBULYSINS | ENDOCYTE, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008101231-A2 | METHODS AND COMPOSITIONS FOR TREATING AND DIAGNOSING KIDNEY DISEASE | ENDOCYTE, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11344623-B2 | Cholecystokinin B receptor targeting for imaging and therapy | CCKBR, CCKAR, GRPR | DPP4 1985/4885ARG1 3769/4885DPP7 1039/4885 |
| US-20230293497-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | DPP4 948/4885ARG1 4409/4885DPP7 457/4885 |
| US-20100004276-A1 | VITAMIN RECEPTOR BINDING DRUG DELIVERY CONJUGATES | VDR, CYP2R1, CYP24A1 | DPP4 1839/4885ARG1 4579/4885DPP7 1413/4885 |
| US-20080248052-A1 | Vitamin receptor binding drug delivery conjugate | VDR, HCAR1, FOLR1 | DPP4 1254/4885ARG1 4651/4885DPP7 1120/4885 |
| US-11369590-B2 | PSMA binding ligand-linker conjugates and methods for using | FOLH1, KLK3, PSMA1 | DPP4 948/4885ARG1 4409/4885DPP7 457/4885 |
| US-11318121-B2 | PSMA binding ligand-linker conjugates and methods for using | FOLH1, KLK3, PSMA1 | DPP4 948/4885ARG1 4409/4885DPP7 457/4885 |
| US-20210338641-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | DPP4 948/4885ARG1 4409/4885DPP7 457/4885 |
| US-20080280937-A1 | Ligand Conjugates of Vinca Alkaloids, Analogs, and Derivatives | VDR, HCAR1, FOLR1 | DPP4 3871/4885ARG1 4511/4885DPP7 3433/4885 |
| US-20230000836-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | DPP4 948/4885ARG1 4409/4885DPP7 457/4885 |
| US-20100048490-A1 | BINDING LIGAND LINKED DRUG DELIVERY CONJUGATES OF TUBULYSINS | TEK, TEKT1, VDR | DPP4 1272/4885ARG1 3464/4885DPP7 525/4885 |
| US-11717514-B2 | PSMA binding ligand-linker conjugates and methods for using | FOLH1, KLK3, PSMA1 | DPP4 948/4885ARG1 4409/4885DPP7 457/4885 |
| US-20230346752-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | DPP4 948/4885ARG1 4409/4885DPP7 457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.